Functional Technologies Signs LOI to Divest Non-Core Assets

April 4, 2012

Functional Technologies (OTC Other: FEBTF; TSX-V: FEB) has entered into a Letter of Intent (“LOI”) to divest its subsidiaries, Phyterra Bio Inc. and Maritime Pulse Drying Inc., as well as the early stage technology and property assets of these subsidiaries, in a management purchase by the President of the Company, Garth Greenham, and its Chief Scientific Officer, Michael Horne. 

Included in the LOI is the transfer of certain federal and provincial government loans and funding associated with these technologies and properties, plant and/or equipment, as well as certain other non-core assets of Functional Technologies and/or its subsidiary, Phyterra Yeast Inc. This is expected to allow for promising early stage applications to be further developed by other parties while reducing the capital and resource burdens to Functional Technologies associated with these non-core obligations.

Read More

Functional Technologies Announces First Quarter 2012 Financial Results

February 28, 2012

Functional Technologies Corp. (TSX-V: FEB; OTC Other: FEBTF) today reported operational and financial results for the first quarter ended November 30, 2011 (Q1 of 2012).

Mr. Christopher Morris, Functional Technologies’ acting CEO stated in the release: “Functional Technologies continues to accomplish substantial achievements in building technical and commercial value for our proprietary acrylamide-preventing as well as hydrogen sulphide-preventing yeast platforms, in alignment with our corporate goal to drive technologies from bench to commercialization. These lead programs continue to achieve significant third party validation for our core technologies, which has also translated into increasing requirements for management time and resources.”

Read More

Functional Technologies’ Acrylamide-Preventing Yeasts Show Well in Studies

February 27, 2012

Functional Technologies (OTC Other: FEBTF; TSX-V: FEB) reports that efficacy studies conducted on end-user materials, investigating the Company’s proprietary acrylamide-preventing (AP) yeast technology in a novel food application that traditionally does not incorporate yeast ingredients as processing aids, have demonstrated significant reduction of asparagine, the main known precursor in the formation of acrylamide. Moreover, the reduction was achieved with short contact times and decreasing yeast dose concentrations. Acrylamide is a chemical shown to be a mutagen (i.e. carcinogenic), as well as neurologically and reproductively toxic. Functional Technologies previously demonstrated that the ability of its technology to reduce asparagine has been significantly effective in preventing the formation of, and thereby reducing, acrylamide.

Read More

Functional Technologies Files GRAS Notification for Acrylamide-Preventing Yeast

February 8, 2012

Functional Technologies (OTC Other: FEBTF; TSX-V: FEB) has submitted to the U.S. Food and Drug Administration (FDA) a Generally Recognized as Safe (GRAS) notification for the Company’s acrylamide-preventing (AP) yeast. Functional Technologies’ subsidiary, Phyterra Yeast Inc., submitted the application to the FDA on the view that this yeast is considered GRAS for use in reducing asparagine levels and thereby preventing the formation of acrylamide during heat-related processing of a variety of foods including grain- and vegetable-based food products (e.g. breads, biscuits, processed potato products, crackers, cereals, etc.).

According to Howard Louie, the Company’s Executive Chairman, “The submission of our GRAS notification to the FDA for our proprietary acrylamide-preventing yeast, as well as any other regulatory applications we may make in the future, are fundamental to Functional Technologies’ demonstration of its commitment towards ensuring safety and quality of the products we have or intend to release to the market.”

Read More

Functional Technologies’ Management Changes to Facilitate Strategic Relationship Development Efforts

January 31, 2012

Functional Technologies (OTC Other: FEBTF; TSX-V: FEB) has appointed Christopher Morris as acting Chief Executive Officer. This enables Mr. Howard Louie, who remains as Executive Chairman and assumes the responsibilities of Chief Business Development Officer, to focus exclusively on the Company’s activities in cultivating and executing on strategic relationships associated with its lead technologies, as well as his ongoing capital market efforts.

Read More

Functional Technologies Appoints COO with Experience in Beverage and Biotech

January 11, 2012

Functional Technologies (OTC Other: FEBTF; TSX-V: FEB) has appointed Kito Tosetti, a seasoned executive in the beverage, food, and biotechnology industries, to the position of Chief Operating Officer.  His responsibilities will initially focus primarily on the comprehensive oversight and direction of Functional Technologies’ operations, and include an active role in increasing the scope of industry applications and markets for the Company’s core products possessing greater value realization opportunities.  The appointment of Mr. Tosetti will enable Mr. Garth Greenham, who remains as President of Functional Technologies, to focus on driving the commercial expansion of the Company’s wine yeast product portfolios, for which the inherent value is growing but has not yet been fully realized.

Read More

Functional Technologies Year End Update

December 29, 2011

Functional Technologies (OTC Other: FEBTF; TSX-V: FEB), according to its CEO, Howard Louie, “has accomplished significant achievements in the past year, particularly in building technical and commercial value for our proprietary acrylamide-preventing (“AP”) yeast platform. This extends from demonstrating compelling efficacy data, to the cultivation of strategic relationships with multiple tier one and tier two yeast producers as well as an increasing range of food processing end users. Our corporate goal to drive technologies from bench to commercialization is being realized with our H2S-preventing wine yeasts, achieving increasing market presence through significant growth in the number of wineries purchasing introductory quantities of our product with results that reflect a strong market interest across several new regional markets. Meanwhile, our technical research and development team continue to improve and increase the quality and breadth of our wine yeast product offering to fulfill our goals to develop and increase market share while establishing the business model of our technology as a platform.”

Read More

Functional Technologies Commences Confirmatory Food Trials With Acrylamide-Preventing Yeasts in Non-Bread, Starch-Based Foods for European Food Processor

November 16, 2011

VANCOUVER, BRITISH COLUMBIA–(Marketwire -11/16/11)- Functional Technologies Corp. (TSX-V: FEB.VNews) (the “Company”) is pleased to announce it has commenced evaluation food trials for a leading European producer of intermediary starch-based food products including extruded snack food pellets (the “Collaborator”), which are purchased and integrated by numerous downstream food manufacturers into a variety of other food products. These downstream food manufacturers represent many brand leaders in the processed food industries, and the Collaborator has established its global position over decades.

In the release, Howard Louie, CEO and chairman of Functional Technologies stated: “Functional Technologies continues to generate validating commercial interest in its yeast platforms, endorsing the appeal of its acrylamide-preventing technologies as a potentially valuable strategy to mitigate the risk of this food contaminant. This collaboration also speaks to the opportunity for the Company’s proprietary yeasts to have critical impact in a wide range of food applications, which is enabled in part by the platform nature of our technologies in being able to address any number of yeast strains to suit the various needs of end-user food producers across multiple sectors.”

Read More

Functional Technologies Announces Next Generation Acrylamide-Preventing Yeast Technology

November 14, 2011

Functional Technologies Corp. (TSX-V: FEB and OTC: FEBTF) announced today the development of a third (3rd) generation of its proprietary acrylamide-preventing (AP) yeast platform, wherein various improvements made to the Company’s original underlying AP technology have enabled the yeast’s capacity to degrade asparagine, the rate-limiting precursor to acrylamide, to be accelerated and elevated.

In the release, Howard Louie, chairman and CEO of Functional Technologies stated: “Functional Technologies’ ability to continuously improve on existing technologies speaks to the strength of the Company’s core yeast competencies, while the results obtained with this latest technology advancement points to the increasing viability for our acrylamide-mitigating platform to meet strict production requirements. These qualities are important in maintaining or even improving the Company’s position with existing and future food industry thought leaders or collaborating companies, in the joint development and potential commercialization of Functional Technologies’ acrylamide-preventing yeasts.”

Read More

Functional Technologies Enters into Evaluation Agreement with Significant European Confectionary Producer

November 10, 2011

Functional Technologies (OTC Other: FEBTF; TSX-V: FEB) has entered into an agreement with a leading European producer of sweet & savoury baked goods, snacks and confectionaries in which the European entity can evaluate the Company’s proprietary acrylamide-preventing yeast technology in its food products.

Regarded as a top-tiered confectionary producer in Europe, the collaboration partner is seeking innovative strategies that mitigate acrylamide in numerous products, but with minimal impact on sensory attributes of the end-product. Given previous successful studies, including in end-user provided commercial materials for the production of non-bread products, the application of the Company’s acrylamide-preventing yeast products are expected to yield valuable, affirmative data. Functional Technologies’ acrylamide-preventing yeast platform will be evaluated in pre-pilot scale trials that simulate commercial conditions, which should also simultaneously enable preliminary development of production protocols. Results obtained from these studies are expected to facilitate meaningful discussions for the Company’s technologies and/or services to subsequently be employed by the collaboration partner.

Read More